Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

NICE guidance informed by SHTAC report on Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma

Published: 20 February 2020
Chemotherapy treatment
Cemiplimab is a possible treatment when patients can’t be treated using surgery or radiotherapy

The National Institute for Health and Care Excellence (NICE) has issued guidance to the National Health Service (NHS) on the use of Cemiplimab as an option for treating locally advanced or metastatic cutaneous squamous cell carcinoma in adult, informed by a report produced by SHTAC.

NICE’s guidance recommends cemiplimab (Libtayo) for use through the Cancer Drugs Fund as an option for treating locally advanced or metastatic cutaneous squamous cell carcinoma in adults when curative surgery or curative radiotherapy is not appropriate. It is recommended only if the conditions in the managed access agreement are followed.

Treatment with cemiplimab should be continued until disease progression or for up to 24 months (whichever is sooner).

These recommendations are not intended to affect treatment with cemiplimab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

More evidence on cemiplimab is being collected, until July 2021. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.

NICE’s guidance is informed by an evidence review group report prepared by SHTAC, which critically appraised the drug company’s submission to NICE’s Single Technology Appraisal process.

For more information about SHTAC’s previous research into cancer please visit our Research page.


Privacy Settings